| | Unaudited For the Fiscal Year Ended | |
(Amounts in thousands) | | (52 weeks) 4/29/2017 | | (53 weeks) 4/30/2016 | |
Cash flows from operating activities | | | | | |
Net income | | $86,984 | | $80,963 | |
Adjustments to reconcile net income to cash provided by operating activities | | | | | |
(Gain) loss on disposal of assets | | (224 | ) | 384 | |
Gain on sale of investments | | (471 | ) | (436 | ) |
Deferred income tax expense | | 569 | | 4,581 | |
Provision for doubtful accounts | | (291 | ) | (660 | ) |
Depreciation and amortization | | 29,131 | | 26,517 | |
Stock-based compensation expense | | 8,864 | | 8,292 | |
Pension plan contributions | | (2,300 | ) | (7,000 | ) |
Change in receivables | | (7,850 | ) | 10,730 | |
Change in inventories | | 12,517 | | (14,621 | ) |
Change in other assets | | (1,211 | ) | 4,148 | |
Change in accounts payable | | 4,541 | | (1,007 | ) |
Change in other liabilities | | 15,915 | | 470 | |
Net cash provided by operating activities | | 146,174 | | 112,361 | |
Cash flows from investing activities | | | | | |
Proceeds from disposals of assets | | 761 | | 3,054 | |
Capital expenditures | | (20,304 | ) | (24,684 | ) |
Purchases of investments | | (29,763 | ) | (21,009 | ) |
Proceeds from sales of investments | | 19,954 | | 28,721 | |
Acquisitions, net of cash acquired | | (35,878 | ) | (23,311 | ) |
Change in restricted cash | | (23 | ) | 659 | |
Net cash used for investing activities | | (65,253 | ) | (36,570 | ) |
Cash flows from financing activities | | | | | |
Payments on debt | | (288 | ) | (508 | ) |
Payments for debt issuance costs | | — | | — | |
Stock issued for stock and employee benefit plans | | 3,566 | | 420 | |
Excess tax benefit on stock option exercises | | 1,737 | | 1,264 | |
Purchases of common stock | | (35,957 | ) | (44,082 | ) |
Dividends paid | | (20,655 | ) | (18,141 | ) |
Net cash used for financing activities | | (51,597 | ) | (61,047 | ) |
Effect of exchange rate changes on cash and equivalents | | 178 | | (688 | ) |
Change in cash and equivalents | | 29,502 | | 14,056 | |
Cash and equivalents at beginning of period | | 112,358 | | 98,302 | |
Cash and equivalents at end of period | | $141,860 | | $112,358 | |
| | | | | |
Supplemental disclosure of non-cash investing activities Capital expenditures included in accounts payable | | $1,795 | | $— | |